Ravinder Kaur1, Minh Pham2, Karl O A Yu1, Michael E Pichichero1. 1. Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. 2. School of Mathematical Sciences, College of Science, Rochester Institute of Technology, Rochester, New York, USA.
Abstract
BACKGROUND: Antibiotic-resistant Streptococcus pneumoniae strains may cause infections that fail to respond to antimicrobial therapy. Results reported from hospitalized patients with invasive, bacteremic infections may not be the same as those observed in a primary care setting where young children receive care for noninvasive infections. Young children experience the highest burden of pneumococcal disease. The aim of this study was to determine the antibiotic susceptibility of S. pneumoniae strains isolated from children in a primary care setting in the post-13-valent pneumococcal conjugate vaccine (PCV13) era. METHODS: This was a prospective collection of 1201 isolates of S. pneumoniae from 2006 through 2016 in a primary care setting. Antibiotic susceptibility testing to 16 different antibiotics of 10 classes was performed. Participants were children aged 6-36 months. Nasopharyngeal swabs were obtained from patients during acute otitis media (AOM) visits and routine healthy visits. Middle ear fluid was obtained by tympanocentesis. RESULTS: After introduction of PCV13, antibiotic susceptibility of pneumococci, especially to penicillin, initially improved largely due to disappearance of serotype 19A, included in PCV13. However, beginning in 2013, antibiotic susceptibility among pneumococcal strains began decreasing due to new serotypes not included in PCV13. In addition to reduced susceptibility to penicillin, the most recent isolates show reduced susceptibility to third-generation cephalosporins, fluoroquinolones, and carbapenems, antibiotics commonly used to treat life-threatening, invasive pneumococcal diseases. CONCLUSIONS: In recent years, pneumococcal nasopharyngeal and AOM isolates from children exhibit reduced susceptibility to penicillin, third-generation cephalosporin, fluoroquinolone, and carbapenem antibiotics. The new strains have a different profile of resistance compared to the pre-PCV13 era.
BACKGROUND: Antibiotic-resistant Streptococcus pneumoniae strains may cause infections that fail to respond to antimicrobial therapy. Results reported from hospitalized patients with invasive, bacteremic infections may not be the same as those observed in a primary care setting where young children receive care for noninvasive infections. Young children experience the highest burden of pneumococcal disease. The aim of this study was to determine the antibiotic susceptibility of S. pneumoniae strains isolated from children in a primary care setting in the post-13-valent pneumococcal conjugate vaccine (PCV13) era. METHODS: This was a prospective collection of 1201 isolates of S. pneumoniae from 2006 through 2016 in a primary care setting. Antibiotic susceptibility testing to 16 different antibiotics of 10 classes was performed. Participants were children aged 6-36 months. Nasopharyngeal swabs were obtained from patients during acute otitis media (AOM) visits and routine healthy visits. Middle ear fluid was obtained by tympanocentesis. RESULTS: After introduction of PCV13, antibiotic susceptibility of pneumococci, especially to penicillin, initially improved largely due to disappearance of serotype 19A, included in PCV13. However, beginning in 2013, antibiotic susceptibility among pneumococcal strains began decreasing due to new serotypes not included in PCV13. In addition to reduced susceptibility to penicillin, the most recent isolates show reduced susceptibility to third-generation cephalosporins, fluoroquinolones, and carbapenems, antibiotics commonly used to treat life-threatening, invasive pneumococcal diseases. CONCLUSIONS: In recent years, pneumococcal nasopharyngeal and AOM isolates from children exhibit reduced susceptibility to penicillin, third-generation cephalosporin, fluoroquinolone, and carbapenem antibiotics. The new strains have a different profile of resistance compared to the pre-PCV13 era.
Authors: Todd A Davies; Y Cheung Yee; Karen Bush; Dan Sahm; Alan Evangelista; Raul Goldschmidt Journal: Microb Drug Resist Date: 2008-09 Impact factor: 3.431
Authors: Patrick K Mitchell; Taj Azarian; Nicholas J Croucher; Alanna Callendrello; Claudette M Thompson; Stephen I Pelton; Marc Lipsitch; William P Hanage Journal: Microb Genom Date: 2019-02-19
Authors: Rama Kandasamy; Stephanie Lo; Meeru Gurung; Michael J Carter; Rebecca Gladstone; John Lees; Sonu Shrestha; Stephen Thorson; Sanjeev Bijukchhe; Madhav C Gautam; Reetu Shrestha; Sunaina Gurung; Bibek Khadka; Lesley McGee; Robert F Breiman; David R Murdoch; Dominic F Kelly; Shrijana Shrestha; Stephen D Bentley; Andrew J Pollard Journal: Lancet Microbe Date: 2022-05-09
Authors: Richael O Mills; Mohammed R Abdullah; Samuel A Akwetey; Dorcas C Sappor; Isaac Cole; Michael Baffuor-Asare; Johan A Bolivar; Gustavo Gámez; Mark P G van der Linden; Sven Hammerschmidt Journal: Microorganisms Date: 2020-12-13
Authors: Santiago Alfayate Miguélez; Genoveva Yague Guirao; Ana I Menasalvas Ruíz; Manuel Sanchez-Solís; Mirian Domenech Lucas; Fernando González Camacho; M Mar Ortíz Romero; Pilar Espejo García; Carmen Guerrero Gómez; Antonio Iofrío de Arce; Laura Moreno Parrado; Rosa M Sánchez Andrada; Eva Cascales Alcolea; Sebastián Lorente García; Pedro Paredes Reyes; Ángela Casquet Barceló; M Luisa López Yepes; Juan José Vigueras Abellán; Gonzalo Sanz Mateo Journal: Vaccines (Basel) Date: 2020-12-28